Tumor Biology

, Volume 35, Issue 2, pp 1095–1100 | Cite as

MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61

Research Article

Abstract

Increasing evidence indicates that microRNAs (miRNAs) participate in almost every step of cellular processes and are often aberrantly expressed in human cancer. Therefore, the discovery of miRNAs may provide a new and powerful tool for understanding the mechanism and treatment of carcinogenesis. The aim of this study was to investigate the functional significance of miR-100 and to identify its possible target genes in osteosarcoma (OS) cells. Here, we found that expression level of miR-100 was significantly decreased in osteosarcoma tissues in comparison with the adjacent normal tissues. The enforced expression of miR-100 was able to inhibit cell proliferation in Saos-2 and MG63 cells, while its antisense oligonucleotides (antisense miR-100) promoted cell proliferation. Moreover, our results further revealed that expression of Cyr61, an extracellular matrix-associated growth factor, was negatively regulated by miR-100. Therefore, we consider that miR-100 acts as a tumor suppressor for osteosarcoma. It may provide novel diagnostic and therapeutic options for human osteosarcoma in the future.

Keywords

Osteosarcoma MicroRNA Cell proliferation miR-100 Cyr61 

Notes

Conflicts of interest

None.

References

  1. 1.
    Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013;14(8):535–48.PubMedCrossRefGoogle Scholar
  2. 2.
    Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14(8):475–88.PubMedCrossRefGoogle Scholar
  3. 3.
    van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011;11(9):644–56.PubMedCrossRefGoogle Scholar
  4. 4.
    Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11(12):849–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Liang W, Gao B, Fu P, Xu S, Qian Y, Fu Q. The miRNAs in the pathogenesis of osteosarcoma. Front Biosci. 2013;18:788–94.CrossRefGoogle Scholar
  6. 6.
    Cai CK, Zhao GY, Tian LY, Liu L, Yan K, Ma YL, et al. miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep. 2012;28(5):1764–70.PubMedGoogle Scholar
  7. 7.
    Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 2012;72(4):908–16.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012;27(4):1238–44.PubMedGoogle Scholar
  9. 9.
    Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11(2):136–46.PubMedCrossRefGoogle Scholar
  10. 10.
    Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer. 2012;12:519.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Chen P, Zhao X, Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013. doi: 10.1007/s11010-013-1753-0.
  12. 12.
    Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, et al. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 2012;31(42):4517–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Gebeshuber CA, Martinez J. miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene. 2013;32(27):3306–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Bai J, Guo A, Hong Z, Kuai W. Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther. 2012;5:213–9.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW, et al. MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene. 2012;31(1):80–92.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Lau LF. CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci. 2011;68(19):3149–63.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lee KB, Byun HJ, Park SH, Park CY, Lee SH, Rho SB. CYR61 controls p53 and NF-κB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett. 2012;315(1):86–95.PubMedCrossRefGoogle Scholar
  18. 18.
    Goodwin CR, Lal B, Zhou X, Ho S, Xia S, Taeger A, et al. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. Cancer Res. 2010;70(7):2932–41.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Lin J, Huo R, Wang L, Zhou Z, Sun Y, Shen B, et al. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother. 2012;61(5):677–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R. Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene. 2002;21(6):964–73.PubMedCrossRefGoogle Scholar
  21. 21.
    Leask A. CCN1: a novel target for pancreatic cancer. J Cell Commun Signal. 2011;5(2):123–4.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Haque I, Mehta S, Majumder M, Dhar K, De A, McGregor D, et al. Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer. 2011;10:8.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Xie JJ, Xu LY, Xie YM, Du ZP, Feng CH, Dong H, et al. Involvement of Cyr61 in the growth, invasiveness and adhesion of esophageal squamous cell carcinoma cells. Int J Mol Med. 2011;27(3):429–34.PubMedGoogle Scholar
  24. 24.
    Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, Bertz J, et al. Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res. 2012;27(1):58–67.PubMedCrossRefGoogle Scholar
  25. 25.
    Fromigue O, Hamidouche Z, Vaudin P, Lecanda F, Patino A, Barbry P, et al. CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J Bone Miner Res. 2011;26(7):1533–42.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Jianhua Huang
    • 1
  • Kanda Gao
    • 1
  • Jian Lin
    • 1
  • Qiugen Wang
    • 1
  1. 1.Department of Orthopaedics, Affiliated People’s First HospitalShanghai Jiaotong UniversityShanghaiChina

Personalised recommendations